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Abstract
Compromised immunity contributes to the decreased ability of the elderly to control infectious
disease and to their generally poor response to vaccination. It is controversial as to how far this
phenomenon contributes to the well-known age-associated increase in the occurrence of many
cancers in the elderly. However, should the immune system be important in controlling cancer, for
which there is a great deal of evidence, it is logical to propose that dysfunctional immunity in the
elderly would contribute to compromised immunosurveillance and increased cancer occurrence.
The chronological age at which immunosenescence becomes clinically important is known to be
influenced by many factors, including the pathogen load to which individuals are exposed
throughout life. It is proposed here that the cancer antigen load may have a similar effect on
"immune exhaustion" and that pathogen load and tumor load may act additively to accelerate
immunosenescence. Understanding how and why immune responsiveness changes in humans as
they age is essential for developing strategies to prevent or restore dysregulated immunity and
assure healthy longevity, clearly possible only if cancer is avoided. Here, we provide an overview
of the impact of age on human immune competence, emphasizing T-cell-dependent adaptive
immunity, which is the most sensitive to ageing. This knowledge will pave the way for rational
interventions to maintain or restore appropriate immune function not only in the elderly but also
in the cancer patient.
Introduction
Cancer is largely a disease of older people; the median age
for cancer diagnosis in industrialised countries is
approaching 70 years of age and is expected to increase
[1]. This can be due to different reasons, such as increased
duration of carcinogenesis or the susceptibility of aging
cells to environmental carcinogens [2,3]. Another mecha-
nism responsible might be reduced immune function,
"immunosenescence", in the elderly. The importance of
the immune system in preventing tumor formation,
termed immunosurveillance, has been repeatedly shown
in animal models and is supported by epidemiological
evidence, such as increased frequency of certain cancer
types in immunosuppressed individuals [4,5]. Here, we
discuss the effects of age on immune-cell development
and function, as well as the dynamics and turnover of
immune cells in the elderly, and speculate as to whether
many of these changes are the result of persistent chal-
lenge by a range of antigen types including cancer anti-
gens. Immune correlates with response to vaccination and
mortality and possible interventions to restore appropri-
ate immunity and enhance responses to vaccination in the
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elderly are also discussed. This will be of crucial impor-
tance not only for vaccination against common pathogens
such as influenza [6], but for the increasing application of
immunotherapy for cancer in the elderly. Especially in the
latter case, the mild or absent side effects of immuno-
therapy compared to chemotherapy of cancer may make
this approach particularly desirable in the frail older can-
cer patient.
Impact of aging on immune parameters
In elderly people, the ability to respond in a versatile way
to pathogens, and potentially to cancer, is reduced due to
dysregulated immunity, a state known as immunosenes-
cence. This is characterized firstly by low numbers of naïve
T cells in the peripheral blood [7] and probably also in
other immune organs such as the lymph node [8], which
is robustly observed in different human populations [9].
There is a corresponding reduction in the diversity of the
naïve T-cell receptor (TCR) repertoire, which helps to
explain the decreased ability of the elderly to resist infec-
tions to which they were not previously exposed, or to
respond to the de novo appearance of tumor antigens. Sec-
ond, although the number of memory T cells increases,
there is a decrease in the diversity and functional integrity
of both the CD4+ and CD8+ T-cell subsets [10,11] which
contributes to the decreased ability of the elderly to
respond adequately to re-infection or to retain memory
for cancer antigens expressed by relapsing tumors. Moreo-
ver, the ability to respond appropriately to persisting
infection or persistent exposure to other antigen sources,
such as cancer antigens, may also be compromised, a
process sometimes termed "immune exhaustion" [12].
The focus of much research on immunosenescence has
been T cells, mainly because antigen presentation by den-
dritic cells (DCs) generally seems well-retained in the eld-
erly [13], and because appropriate B cell [14] function
depends on helper T cells. This is not to imply that non-
clonotypic immunity is entirely resistant to age-related
changes, or unimportant, but the alterations to natural
killer (NK) cells and other innate immune cells [13] seem
to be less marked than those seen with T cells. Nonethe-
less, it has been reported that NK cell status can predict
morbidity and mortality in the elderly, emphasizing the
importance of innate as well as adaptive immunity in
ensuring healthy longevity and possibly cancer resistance
[15]. In addition, and at least partly because of innate
immune activity, the levels of pro-inflammatory factors
are commonly increased in the elderly and are associated
with negative effects on health [16]. Together, these
changes contribute to morbidity and mortality, and are
associated with poor responses to vaccination against
pathogens such as those causing influenza and pneumo-
nia [17], leading to decreased quality of life and increased
health-care burdens in later life.
Studying immune cells directly ex vivo, as well as in culture
models of ageing in vitro, has contributed to our under-
standing of age-associated changes in human T-cell-medi-
ated immunity. However, exactly which factors are most
important in immunosenescence and what causes these
age-associated changes remain largely unclear. Accumu-
lating data initially unexpectedly implicated infection
with persistent herpesviruses, particularly cytomegalovi-
rus (CMV), as contributing to the age-associated changes
observed in many studies of human immune ageing [18-
22]. By analogy, long-term exposure to other persistent
stimulating agents, possibly parasite antigens rather than
CMV, especially in developing countries, as well as dysreg-
ulated responses to autoantigens and cancer antigens,
may yield similar effects. Clearly, more detailed knowl-
edge of the reasons for immune dysfunction at advanced
age and development of strategies to prevent or reverse
this should contribute to maximizing healthy lifespan for
the ever-growing numbers of elderly people in industrial-
ized and, increasingly, in industrializing countries.
Immune-cell development
The cells of the immune system turn over rapidly, so com-
promised production or function of haematopoietic stem
cells (HSCs) would affect all aspects of immunity down-
stream [23]. There is evidence for an association between
HSC decline and longevity [24] probably due to differ-
ences in DNA damage repair [25,26]. Purified HSCs from
old mice have less ability to reconstitute haematopoiesis
[27]. It has been recently suggested that the observed age-
associated skewing of hematopoiesis away from lym-
phocyte generation may be one of the factors contributing
to increased cancer occurrence with age [28]. There is also
a gradual decline in the ability of mouse HSCs to progress
through the various B-cell differentiation stages, partly
reflecting microenvironmental changes. These may
involve altered production of interleukin-7 (IL-7) by stro-
mal cells [29]. Changes at the level of T-cell progenitors
also contribute to age-associated deficits in mice [30]. In
any event, age is likely to impact both on HSCs and the
niche environment that determines their fate (Figure 1).
Although even the very elderly can retain some degree of
thymic function [31], thymic involution which represents
the next hurdle that a T-cell progenitor must overcome in
order to develop into a mature naïve T cell. That this could
be clinically important in cancer is demonstrated in a
study of age-dependent glioma-associated mortality, in
which the numbers of CD8+  recent thymic emigrants
accounted for the effect of age on clinical outcome [32].
However, assessing immune reconstitution after HSC
transplantation has demonstrated exceedingly low levels
of thymic activity after the age of around 40 years [33].
Exactly why thymic involution occurs remains unclear.
Because the most marked (but not the only [34] changesImmunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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to thymic size and structure occur around puberty, it has
been suggested that increased levels of sex hormones con-
tribute to causing thymic involution; thymic output of
naïve T cells can increase in both mice and humans fol-
lowing androgen ablation [35,36]. Nevertheless intrinsic
defects in the commitment of haematopoietic stem cells
to the lymphoid lineage [37] and the migration of T-cell
progenitors into the thymus have also been implicated in
this process [38]. Whatever the reason, it is clear that
major age-associated changes to the thymus and greatly
decreased output of naïve T cells are observed in both
mice and humans (Figure 1). The elderly must therefore
increasingly rely on naïve T cells already previously pro-
duced and the small numbers possibly still being pro-
duced. The presence of cancer, or particularly the
treatments applied as cancer therapy, are also likely to fur-
ther compromise any residual thymic function [39].
Innate-adaptive immune interactions
In the next stage in T-cell-dependent immunity, naïve T
cells must be activated by appropriate contact with anti-
gen-presenting cells (APCs), such as DCs (Figure 2).
Although DCs seem to be only subtly different in the eld-
erly in many respects [40], there are quantitative differ-
ences, with less peripheral blood [41] and follicular DCs
[42]. Chemotaxis and phagocytosis may be impaired in
DCs, as well as neutrophils [13], from the elderly [43].
DCs from young and elderly people are reported to stim-
ulate naïve CD8+ T cells equally well, but those from the
elderly may fail to stimulate naïve CD4+ T cells properly
[43], perhaps due to altered signal transduction pathways
involving phosphoinositide 3-kinase signalling [44]. In
cancer, the effect of the tumor on the APC may enhance
these deficits [45]. Many active immunotherapy protocols
for cancer patients rely largely on DCs to be recruited to
the site of vaccination and take up the vaccine antigen.
Reduced DC numbers as well as their chemotactic and
phagocytic activity in the elderly might represent another
hurdle to be overcome in developing successful vaccina-
tion strategies for elderly cancer patients.
One very good example of the interplay between innate
and adaptive immunity is illustrated by γδ-T cells [46],
which also show age-associated alterations. These are able
to recognize phosphoantigens present on cancer cells and
have anti-tumor activities, as well as other functions, such
as anti-CMV activity [47]. Their numbers rise from birth to
puberty and gradually decrease again beyond 30 years of
Impact of ageing on immune cell development Figure 1
Impact of ageing on immune cell development. Genetic and environmental influences modulate age-associated altera-
tions to the number and function of HSCs in the BM, resulting in skewed production of leukocytes. Reduced production of T 
cell progenitors, together with age-associated thymic involution, results in a relatively larger impact of age on T cells than on 
other leukocytes.Immunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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age, and they show functional alterations [48,49]. A func-
tional analysis in young/adult and middle aged donors
revealed that effector/memory γ9/δ2 CD27- T cells are
increased after in vitro culture in the presence of specifi-
cally stimulatory isopentenylpyrophosphate and IL-2 for
10 days. In contrast, this did not occur when using cells
from old subjects, confirming a lack of naive and central
memory cells responding to IL-2 [50,51]. In these
respects, γδ T cells behave quite similarly to conventional
αβ T cells, as discussed in the next section.
T-cell function and ageing
Changes at the single-cell level
To mediate an adaptive immune response, T cells must
interact with functional APCs, become activated and
undergo extensive clonal expansion, followed by clonal
contraction. Alterations in either the number or the struc-
ture of cell-surface receptors, as well as their location in
the membrane, and, once assembled, their intracellular
signalling pathways, could all contribute to the final out-
come of each T-cell-DC interaction. Studies have focused
on alterations in signal transduction as well the formation
of signalling domains (such as the immunological syn-
apse). The interpretation of much of the published data is,
however, complicated by the use of samples consisting of
varying proportions of the different T-cell subpopulations
in each individual, which cannot be assumed to manifest
identical age-related changes.
There is no evidence for alterations to the actual structure
of TCRs or co-stimulatory receptors with age, but it is
likely that their assembly into functional units is compro-
mised, leading to alterations in the assembly of the signa-
losome (Table 1). One major factor that influences TCR
assembly is cell membrane fluidity, as first suggested
many years ago [52]. However, this changes according to
systemic fatty-acid availability, as illustrated by infusing
lipids into young volunteers [53], and not necessarily as a
result of ageing. Nonetheless, the increased levels of cho-
lesterol which occur commonly in the elderly might well
contribute to age-associated deficits in T-cell signalling
[54]. High cholesterol levels are also found in some can-
cers, at least before the metabolic dysregulation caused by
the tumor results in their lowering as the disease
progresses (see, for example, [55,56]).
Although the number of TCR molecules per T cell does
not seem to change with age [57], there are clear altera-
tions in the number and balance of receptors that mediate
positive or negative co-stimulatory signals. Decreased or
Age-associated changes to DCs Figure 2
Age-associated changes to DCs. Reduced numbers and functions of of DCs, together with reduced numbers of naïve T 
cells in the periphery of aged individuals further conspire to ensure that T cell function is depressed in the elderly due to the 
relative decrease in T helper cell activation.Immunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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absent expression of the most studied of these cell-surface
molecules, CD28, is commonly referred to as a biomarker
for immunosenescence [58], because highly differentiated
CD28- T cells, especially within the CD8+ T-cell subset,
tend to accumulate in the peripheral blood of the elderly
and because CD28 expression is lost after extended cul-
ture in vitro as T cells undergo differentiation and enter a
state of replicative senescence [58]. Studies of cultured T
cells have confirmed that decreases in CD28 expression
do occur within monoclonal populations as they undergo
clonal expansion and progress through their finite
lifespan, excluding the possibility that a small population
of originally CD28- cells overgrows the CD28+ cells [59].
Nonetheless, the definition of such changes as biomarkers
of immunosenescence remains problematic, because, for
example, CD28 is downregulated by tumour-necrosis fac-
tor (TNF) [60] and upregulated by IL-12 [61], not neces-
sarily associated with senescence. It has also been difficult
to establish whether the much-investigated altered signal
transduction pathways in T cells are a result of an altered
balance of expression of positive and negative co-stimula-
tory receptors [62,63], determining the final outcome –
activation, anergy or apoptosis of the T cell. Further stud-
ies on clonal populations in culture should facilitate dis-
tinguishing between changes caused by altered
proportions of cell subsets and changes within the same
clones at different times; a first global gene expression
analysis of early and late passage T-cell clones has revealed
a wide range of differentially expressed genes, including
those encoding proteins involved in signal transduction
and apoptosis [64]. Regarding TCR signalling in young
and old T cells, even here, the differences between naïve
and memory T cells, as well as between CD4+ and CD8+ T
cells, are not well documented. For example, the well-
known age-associated decrease in activation of the SRC-
family protein tyrosine kinase LCK, which is one of the
earliest events after TCR ligation and thought to be essen-
tial for T-cell stimulation, was recently shown to be crucial
only for naïve T cells (at least in mouse CD8+ T cells) [65],
of which the elderly simply possess fewer.
Changes at the cell population level
Naïve T cells express CC-chemokine receptor 7 (CCR7)
and leucocyte common antigen isoform CD45RA [66]
and have long telomeres [67], whereas many memory T
cells express the alternative splice variant CD45RO, have
lost CCR7 and have shorter telomeres [68] suggesting an
extensive proliferative history due to lack of telomere
maintenance. The advent of polychromatic flow cytome-
try is facilitating the ever-finer ex vivo dissection of differ-
ent T-cell subpopulations and the changes in their
proportions with age. The best biomarker of immune age-
ing remains the relative levels of naïve T cells (defined as
CD45RA+CD27+CD28+CD62L+CCR7+) and memory cells
(with a wide range of other phenotypes [69] and which
also exhibit age-related differences in TCR diversity, tel-
omere lengths and various other factors). To mount an
adequate response, a broad TCR repertoire must be main-
tained by ensuring the continuing presence of a diverse
population of T-cell clones, but this decreases with age. At
least for CD4+ T cells, this may occur quite suddenly, with
TCR diversity well maintained up to the age range of
60–65 years, despite the marked decrease of thymic out-
put. However, repertoire diversity in 75–80 year olds is
severely reduced [10] and probably contributes to the
poor responses to infection and vaccination in this age
Table 1: Impact of age-associated signalling changes
Features altered Resulting altered mechanism
Cholesterol level Signalling molecule recruitment [135]
Membrane fluidity Protein interaction [54]
Lipid raft functions Early signalling/immune synapse formation [135]
Calcium influx Induction of T cell activation
Phosphatase activity Control of negative signalling
PTK (Lck) activity Phosphorylation of LAT [57,135]
LAT phosphorylation Activation of LAT-associated molecules
MAP Kinase activation Cellular activation/survival [57,135]
Cytoskeleton rearrangement Cell-cell contact/Immune synapse formation
Translocation of transcription factors Induction of gene expression
CD28 expression T cell costimulation/anti-apoptotic signals [58]
KIR expression Formation of an activation platform
KLRG-1, CD57, PD-1 expression Induction of T cell activation [92,158]
For activation, T cells require sustained physical contact with APC. This feature is altered with age due to changes in the integrity of the membrane. 
Several signalling molecules fail to be activated with age, including PTK and adaptor proteins such as LAT. Calcium metabolism is altered, partly due 
to impaired PLCγ-1 phosphorylation. The alterations including lipid raft functions influence MAP Kinase activation and cytoskeletal rearrangements, 
together leading to differential activation and translocation of transcription factors such as NF-κB, NF-AT and AP-1 into the nucleus. This directly 
affects T cell clonal expansion due to decreased IL-2 production. Unbalanced negative signalling involving inhibitory receptors such as KIR2DL2 or 
Natural Killer Receptors contribute to reduce activation. PTK: protein tyrosine kinase; LAT: linker for activation of T cells; MAPK: Mitogen 
activated protein kinase; KIR: inhibitory killer immunoglobulin-like receptors; PLCγ-1: Phospholipase C-gamma 1.Immunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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group (Figure 3). The likely clinical implications of this
are reflected in the close correlation between the diversity
of the repertoire and remaining survival time in very old
people [11]. One explanation for these events could be
that because T cells are maintained in a state of constant
turnover in the body, which is either antigen driven or
homeostatic, replicative senescence (proliferative exhaus-
tion) occurs [70]. In cell culture, CD4+ T cells become
more susceptible to apoptosis at this time of proliferative
exhaustion [71], whereas CD8+ T cells become apoptosis
resistant [72]. The implication of these results is that in
vivo, CD8+ T cells would accumulate and CD4+ T cells
would be lost by clonal deletion, and the CD4+:CD8+ T-
cell ratio would therefore change. There is indeed evi-
dence for the accumulation of CD8+ T cells in vivo, and for
their correlation with poor outcomes to vaccination and
with mortality, as discussed in more detail below.
Immune cell dynamics and turnover
Despite decreased thymic output of T cells, in healthy peo-
ple, the overall number of T cells in the periphery remains
remarkably constant at different ages, although there may
be an association between slightly lower levels of both
CD4+ and CD8+ cells and mortality at 10-year follow-up
[73]. Until recently it was impossible to determine which
cell subsets were proliferating and whether the rate of
expansion was different in people of different ages. Pio-
neering work in which deuterated glucose is incorporated
into dividing lymphocytes to distinguish the fraction of
the pool that proliferates during the labelling time is tech-
nically challenging but very informative in humans and
has now been applied to T cells, B cells and NK cells. In
naïve, memory and regulatory T-cell subsets, label uptake
and loss occurs rapidly but at different rates in each sub-
set, thus indicating divergent rates of cell division, with
regulatory T cells proliferating most rapidly [74]. How-
ever, the only substantial difference between young and
old donors is that the CD8+ memory T cells have a much
longer half-life than any other subset in the elderly, but
not in the young [75]. These results are consistent with an
accumulation of CD8+ T memory cells in the elderly. In B
cells, there are also only slight differences between young
and old individuals, with memory B cells turning over
more rapidly than naïve B cells [76], whereas in NK cells,
the production and proliferation rates were lower in the
elderly than in the young [77]. Nonetheless, B cell mem-
ory may be maintained for a very long time; thus, it has
been recently shown that individuals who survived the
Spanish flu (H1N1) still have specific antibodies 90 years
after the epidemic. These donors still possess circulating B
cells that secrete antibodies that binding the respective
recombinant haemagglutinin protein [78].
Given the high measured levels of peripheral T-cell turno-
ver, it is not surprising that their proliferative potential
eventually becomes exhausted; these exhausted cells are
characterized by a lack of CD27, CD28 and telomerase
expression [79], and by having short telomeres [80].
Memory T-cell turnover may not only result in an eventual
loss of the cells, but also in an active acquisition of sup-
pressive activity as demonstrated in vitro [81] and more
recently in vivo, suggesting that development of regulatory
T cells (Tregs) from terminally-differentiated CD4+ cells
can take place [74]. Tumor antigens as the driving force in
this process might account for the commonly-observed
higher levels of Tregs in cancer patients, which are
believed to be a bad prognostic sign, and to interfere with
immunotherapy [82]. Mechanisms therefor may include
competition for antigen on the DC surface, or altered
cytokine secretion patterns [59]. At least for pathogens
establishing only acute infection, antigen seems not to be
required for the constant turnover of specific memory T
cells. In mice after clearance of acute viral infection, mem-
ory T cells persist for the lifetime of the animal and also
undergo clonal expansions and accumulate even in the
absence of the original antigen [83]. Thus, T-cell clonal
exhaustion may be an intrinsic characteristic of adaptive
immunity, which still occurs even in the absence of
chronic infection [84]. However, the biological norm is
likely to be chronic infection; in humans, mostly herpes
Hypothetical model for the evolution of T cell immunity over  the human lifespan Figure 3
Hypothetical model for the evolution of T cell immu-
nity over the human lifespan. Age-associated changes to 
T cell immunity result in decreasing proportions of naïve cells 
and increasing proportions of memory cells over the lifespan. 
TCR repertoire diversity is well-maintained at least until the 
end of the reproductive period, when repertoire shrinkage 
occurs rapidly. This point is reached as the number of differ-
ent clonal expansions caused by persistent pathogens, as 
demonstrated for CMV, plateaus and then decreases. Loss of 
repertoire diversity in memory cells is not paralleled by their 
decreased numbers; on the contrary, these continue to rise 
as dysfunctional cells accumulate, possibly a compensatory 
mechanism. At this time also, responses to vaccination, as 
documented with influenza vaccination, are much less effec-
tive than at earlier time points.Immunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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viruses, especially CMV and in CMV-negative elderly indi-
viduals, Epstein-Barr virus (EBV), may be the main agents
driving CD8+ T cells to exhaustion [85]. In different envi-
ronments, possibly where EBV and CMV are not so preva-
lent, other pathogens may play a similar role. Analogous
phenomena of clonal exhaustion and senescence may
also occur in HIV disease [86] and autoimmunity [87,88],
and, as we argue here, cancer. Although the proliferative
reserve of T cells is high, at least until telomere erosion
reaches its critical limit (termed the Hayflick limit), being
approximately 70 population doublings for CD4+ T cells
[70], the old idea that T-cell clonal exhaustion leads to
clonal attrition and has clinical consequences has stood
the test of time. The clinical consequences may be broad
and impact not only on those very advanced in years, as
discussed in the next section.
Immune biomarker correlates with response to vaccination 
and mortality
Establishing reliable biomarkers identifying T-cell subsets
and determining which are the most relevant to healthy
ageing and adequate responses to vaccination requires
longitudinal studies following the same individuals over
time and correlating test parameters with clinical outcome
(such as mortality, pathology and vaccination responses).
Cross-sectional studies have the disadvantage that the
young and old populations compared will have differed
tremendously in their previous exposure to environmen-
tal factors of all kinds, and probably, also genetic consti-
tution. However, so far, most human studies have been
cross-sectional, and because of logistical constraints we
cannot even be sure whether acute infectious complica-
tions are really more severe in the elderly due to impaired
innate and adaptive immunity or due to other factors.
Apparently simple questions such as the correlation of
immune status with outcome of vaccination in the elderly
cannot yet be answered definitively. Correlations between
the presence of certain T-cell subpopulations and poor
responses to vaccination against influenza virus have,
however, been reported. Excessive CD8+CD28- T cells cor-
relate with poor responsiveness, whereas, counter-intui-
tively, frequencies of CD4+ memory T cells, regardless of
CD28 expression, do not [89]. In mouse models, the virus
is cleared from the lungs more slowly in old than young
mice, correlating with a delayed and decreased peak of
cytotoxic T-cell production. Thus, cellular responses are
crucial for controlling the virus but do not function ade-
quately in old animals; this appears to be likely in humans
too [90]. In mice, cell transfer experiments demonstrated
that it was both the old environment and the old cells that
contributed to the problem – that is, even young func-
tional T cells do not respond properly when transferred to
an old environment (and neither do old T cells when
transferred to a young environment) [91].
The apoptosis-resistant cells that accumulate in both old
mice and humans may be dysfunctional in several ways.
In young mice, the number of T cells staining with soluble
MHC/peptide multimers loaded with influenza-virus
epitopes is very similar to the number of T cells producing
interferon-γ (IFNγ) on antigen stimulation, indicating
that essentially every antigen-specific cell present is able to
respond to antigen. However, in old mice, the number of
tetramer-positive cells exceeds the number of IFNγ-pro-
ducers, indicating that a proportion of the antigen-specific
cells fails to respond. This is quite similar to the situation
in very elderly individuals who accumulate large clonal
expansions of CMV-specific T cells, the majority of which
are dysfunctional (or anergic). Longitudinal studies of
elderly Swedes have established that individuals with the
largest accumulations of clonally expanded CD8+ T cells,
most of which are CMV-specific and have a mature phe-
notype (CD27-CD28-CD57+KLRG1+) [92,93], have a
shorter remaining survival time than people of the same
age with less of these cells at baseline. In CMV-positive
subjects, the number of different clonal T-cell expansions
increases from middle age to old age and decreases in the
terminal phase of life, resulting in a highly significant cor-
relation between the number of T-cell clones and survival
of the individual [11]. This finding suggests that eventual
loss of control of CMV infection after a lifetime of immu-
nosurveillance may indeed be a cause of mortality in this
elderly population (Figure 4). Whether this will be a gen-
eral finding in other populations remains to be seen.
Clonal expansions of CD8+ T cells are also found in old
mice; whether this is antigen independent (random TCR
usage; homeostatic proliferation) or antigen driven may
depend on the pathogen environment [94]. Thus,
although antigen driven, especially CMV-stimulated, T-
cell clones may be the type most frequently found in aged
humans, this finding suggests that there are multiple,
independent mechanisms that can contribute to age-
altered CD8+ T-cell homeostasis. All these findings suggest
that dysfunctional, end-stage differentiated cells may
accumulate in various physiological situations [95]. To
what extent this process is amplified in CMV carriers who
are also cancer patients, and not only for CD8+ but also
CD4+ T cells as well as possibly components of innate
immunity [13,96] must be further investigated. This
notion is consistent with the hypothesis that such CD8+
cells fill the "immunological space", thereby decreasing
immune competence and raising the possibility of inter-
vening to restore appropriate immunological function
[97,98]. As we learn more about the dysfunctional status
of these cells, in terms of basic biochemical functions
[99,100] and receptor signalling [101] we may begin to
identify biomarkers that can be used in monitoring ther-
apy success [102,103]. There is some evidence for the
existence of such "exhausted" cells in cancer patients
[104,105]. Whether the accumulation of dysfunctionalImmunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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cells can influence response to therapy, in particular to
immunotherapy in cancer patients, remains to be
explored; very few approaches to this question have been
made so far, but a limited literature exists in animal mod-
els.
Cancer immunity and ageing
The extent to which tumors are controlled by immunity is
controversial. Nonetheless, there is clear evidence for the
immunogenicity of cancer cells and large numbers of can-
cer immunotherapy trials have shown beyond reasonable
doubt that T cells recognizing tumor antigens can be
amplified in many patients. The calculated frequency of
cells responding to a vaccine antigen (MAGE-3) in
melanoma suggests that responding T cells must divide a
large number of times to generate the observed number of
responding cells and to be effective in patients [106]. This
extreme requirement for clonal expansion might well be
partially responsible for the lack of success of many cancer
vaccination trials, due to the phenomenon of replicative
senescence in T cells [70].
Limited studies in preclinical animal models have indi-
cated age-associated alterations in tumor immunity and
therapeutic responses. Thus, in a mouse breast cancer
model, there are effective anti-cancer immune responses
in young animals which are mostly mediated by T cells,
whereas the (less effective) responses in old animals pri-
marily rely on innate immunity [107]. This could be a
general finding, because adaptive immunity is highly sus-
ceptible to deleterious changes with age, but innate
responses tend to be better-preserved [108]. In fact, reten-
tion of strong inflammatory responses with age, but now
in the absence of the counterbalancing and beneficial
effects of the adaptive responses that they normally
amplify at younger age may even enhance immunopa-
thology and carcinogenesis. This might also help to
explain the genetic component of certain cancers in which
inflammation is well-established as an amplificatory fac-
tor [109]. On the other hand, tumors may be less aggres-
sive in the elderly, as seen in breast, lung, colon and other
sites in very old people and centenarians, partly because
of the lower inflammatory status of "successfully aged"
people, which also decreases the ability of the stromal tis-
sue to support tumour growth and angiogenesis [110].
According to these considerations, young and old individ-
uals will most likely require different treatment
approaches, which could solve some of the problems of
treating geriatric cancer patients with other, more tradi-
tional, modalities. Cancer could be less responsive to
chemo- and radiotherapy in the elderly, and this might be
because the immune system is less effective in the elderly,
following the notion that even responses to chemo- and
radiotherapy require an intact immune system [111]. In
the few animal models investigated thus far, cancer
immunity successful in young individuals is mostly less
effective in older ones. Young mice injected with highly
immunogenic tumors such as chemical- or radiation-
induced sarcomas controlled the tumor better compared
Decreasing regenerative reserve in immunosenescence Figure 4
Decreasing regenerative reserve in immunosenescence. Hypothesis: In the elderly, dysfunctional, often CD8+ CMV- 
specific T cells accumulate because apoptotic pathways are compromised. Vital memory cells are eventually lost by clonal attri-
tion (clonal exhaustion). Loss of memory cells for previously encountered pathogens contributes to morbidity and mortality. 
Thus, decreased clonal heterogeneity correlates with mortality in longitudinal studies. Because T cell homeostasis maintains constant 
numbers of T cells in the periphery, even the age-associated decreased thymic-output of naive cells is blocked, and the shrink-
age of the naive T cell repertoire contributes to increased susceptibility to newly-encountered infectious diseases. IM, infec-
tious mononucleosis; PD, population doublings.Immunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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to old mice. In contrast, tumors with weak immunogenic-
ity, like B16 melanoma, were more aggressive and grew
better in young animals compared to old (reviewed in
[112]). Sometimes, decreased efficacy in old mice can be
compensated for by increasing costimulation [113,114],
which is focussing efforts on improving adjuvants for the
purpose of better vaccination results in the elderly in gen-
eral. This may be particularly important given the possible
synergistic effects of ageing and cancer on DC function,
such that the relative contribution of DC dysfunction may
be greater in cancer than in healthy ageing [115]. How-
ever, as with other aspects of the complex interactions
between cancer and ageing, it will be difficult to generalize
from one system to another. Thus, it has already been
demonstrated that some immunotherapies are actually
effective only in old but not young animals [116], imply-
ing that patient-individualized therapies will have to take
the immunological age of the individual closely into
account. For this, it will clearly be necessary to differenti-
ate between chronological age and the "functional" age of
immunity, as could be based on the constellations of
immune markers making up the "immune risk profile" or
the modified set of markers investigated by Hirokawa et
al. mentioned above [105].
Possible interventions and improved vaccination strategies
As discussed above, immunosenescence results from mul-
tifactorial processes that act on all components of the
immune system and some approaches to reconstitute
appropriate function have already been mentioned.
Recent results from studies on long-lived non-human pri-
mates maintained on a calorie-reduced diet showing
improved maintenance and/or production of naïve T
cells, better T-cell function and reduced pro-inflammatory
status [117], and the possible beneficial effects of moder-
ate exercise [118], serve to emphasize the continued rele-
vance of common-sense medical advice in "anti-ageing"
medicine as applied to immunosenescence. Although as
ageing proceeds, the T- and to some extent B-cell compart-
ments seem to be particularly susceptible to senescence,
NK cells and other components of innate immunity are
also affected. As mentioned above, some limited data do
point to a crucial impact of NK-cell status on resistance to
infectious disease and hence healthy longevity [15], as
well as being implicated in the outcome of influenza vac-
cination [119]. It is likely that NK cells also play a role in
determining the outcome of cancer immunotherapy
[103]. Clearly, it is not only the T-cell status and/or CMV
status of elderly subjects that affects the outcome of vacci-
nation [120], but also the pre- (and post-) vaccination
NK-cell status [119] (although how much the latter is
affected by CMV is not yet clear). It is therefore imperative
that these studies are extended and repeated in different
populations. Nonetheless, the most severe clinical impact
is likely to remain primarily the result of loss of TCR and
BCR repertoire diversity due to clonal deletions, decreased
thymic and bone marrow output, and accumulations of
dysfunctional cells. In addition to avoiding over-eating
and ensuring that sufficient exercise is taken, what else can
be done to reconstitute immunity at old age?
Restoring naive T-cell number and function
Given the paucity of naïve T cells in the elderly, enhance-
ment of thymic output is likely to be a first requirement
for maintaining or restoring their effective immunity.
However, although in a contrived experimental situation
in mice, neonatal thymi grafted under the kidney capsule
exported the same numbers of T cells regardless of
whether the peripheral pool was oversupplied (by thymic
grafts) or undersupplied (due to neonatal thymectomy)
[121], feedback mechanisms maintaining T-cell homeos-
tasis in humans would be expected to prevent any residual
thymic output due to the accumulated dysfunctional
CD8+ T cells present in the periphery. This may be consist-
ent with age-associated decreases in thymic output of
CD8+ T cells being more marked than CD4+ T cells, at least
in mice [122]. Such CD8+ T-cell accumulations could be
reduced or eliminated by identifying ways of specifically
targeting the dysfunctional subset [98]. Efforts directed at
thymic reconstitution could then follow.
In mice, it was reported that transplantation of aged invo-
luted thymi into juvenile recipients led to reconstitution
of the structure and function of the thymus [123]. Moreo-
ver, transplantation of cultured thymic fragments to
patients with DiGeorge syndrome who lack a functional
thymus, has been carried out successfully [124] and may
also be a conceivable approach to restore naive T-cell
numbers in the elderly. The use of T-cell survival factors,
such as IL-7, has been explored in mice and monkeys, and
local delivery of this cytokine to the thymus by implanta-
tion of genetically engineered stromal cells secreting it
may be a way of avoiding systemic effects [125]. Sex ster-
oid ablation in men undergoing therapy for prostate can-
cer is reported to result in increased numbers of
circulating naïve T cells, but this approach is obviously
not generally applicable to the majority of elderly people
[35]. More recently, other factors such as keratinocyte
growth factor have been shown to improve thymic output
in old mice [126]. Thymic epithelial cells, which are
required to support thymocyte maturation, undergo
apoptotic death in the aged thymus, through a pathway
involving interactions between FAS and FAS ligand.
Because age-associated thymic involution is reported not
to occur in aged FAS-deficient mice [127], blocking this
pathway locally in the thymus might also contribute to
retaining thymic functionality. The same may apply to
transforming growth factor-β2 (TGFβ2), as greater thymic
cellularity and higher levels of naive T cells are seen in old
TGFβ2-deficient mice compared to old wild-type miceImmunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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[128]. T cells that have undergone clonal exhaustion after
chronic viral infection also express the B7-family receptor
named programmed cell death-1 (PD1), that inhibits co-
stimulatory signals [129]. It has been suggested that
blocking PD1-mediated signalling could lead to
improved T-cell function [130].
It is too early to say whether any of these approaches can
be translated to human therapy. It is possible that, among
its other effects, CMV has a role in reducing thymic out-
put: at least in clinical human HSC transplantation, out-
put of naïve T cells is reduced by CMV infection [131].
Steps taken to reduce CMV infection might therefore also
benefit naïve T-cell production.
Nutrition and inflammation
Interventions in nutrition, which are relatively easy to
carry out, could have a larger impact on immune function
than commonly appreciated, even in donors selected for
very good health [132]. Vitamin E supplementation has
received much attention, and was recently reported to
reconstitute immunological synapse formation, especially
in CD4+ naïve T cells of old mice [133]. However, many
nutritional interventions could be viewed more as correct-
ing poor diet, or reducing an inappropriately rich diet, but
this alone could have a major impact on immunity in the
elderly. Given the notion that increased basal levels of
inflammation and frailty in the elderly are intimately
related, anti-inflammatory nutritional interventions
could be useful [16]. Modulating lipid intake would be a
possibility in this context, using, for example, conjugated
linoleic acid, which can result in decreased pro-inflamma-
tory cytokine secretion and which can increase the success
rates of hepatitis B vaccination in the elderly [134]. As dis-
cussed above, the lipid environment strongly influences
T-cell function, and alterations in membrane fluidity
affect lipid raft and immunological synapse formation
[52,135]. Human high-density lipoprotein extracts accu-
mulated cholesterol from lipid rafts, resulting in increased
TCR signal transduction and T-cell activation [136].
Use of non-dietary anti-inflammatory agents to decrease
levels of IL-6, TNF and IL-1 may also assist in rebalancing
immunity; to this end, it might be possible to use rela-
tively innocuous agents, such as statins, that are already
being used extensively in the elderly to treat autoimmu-
nity and other diseases [137]. In particular, the level of IL-
6 was found to be an independent predictor of mortality
in longitudinal studies, which, together with a cluster of
immune parameters designated the immune risk profile
(IRP, see next section), constituted a super-additive risk of
mortality [138]. However, the efficacy of any approach to
influence inflammation is very much open to question, as
inflammation also has protective effects against patho-
gens. From a theoretical point of view, given clear associ-
ations of IL-6, for example, with frailty [139], reducing the
levels of such mediators would nonetheless be beneficial
not only for improving immune status, via improved anti-
gen presentation [140], for example, but also by its effect
on many other organ systems. Given the contribution of
inflammation to carcinogenesis, there may well be benefit
of using anti-inflammatories in this context as well. Nutri-
tional intervention by caloric restriction, that was shown
to improve the immune response in rodents [141], has
also been shown to delay T cell immunosenescence in
non human primates, preserving the number and func-
tion of naive T cells [117].
Antigenic load
Given the initially quite unexpected impact of infection
with persistent herpesviruses on immunity in the elderly
[19] strategies to reduce the infectious antigenic load
would seem to offer a reasonable approach to restoring
appropriate immunity. The Swedish OCTO/NONA longi-
tudinal studies [142] have revealed several changes in
immune parameters predicting mortality at 2, 4 and 6 year
follow-up, and summarized in what we have designated
the IRP [143]. This is a cluster of immune biomarkers
which may be informative in several elderly populations
[144,145], as well as in other circumstances, for example,
for the occurrence of infections after HSC transplantation
[146] and autoimmunity [88]. An initially surprising find-
ing was the association of the IRP in the elderly with CMV
infection [147], but not with morbidity [148], which is
consistent with the effect of persistent herpesvirus infec-
tions on immunity. A recent study [149] has also shown a
progressive accumulation of HSV-specific T cells with a
central memory phenotype in old mice. However the con-
tinuous administration of antiviral drugs did not alter the
course of this accumulation of T cells. These results sug-
gest the possibility that, at least in this experimental
model, T cells expansions arise as a consequence of age-
associated homeostatic disturbances rather than repeated
antigenic stimulation. Nevertheless, the direct influence
of CMV and other herpes viruses as a major driving force
in T cell immunosenescence cannot be excluded. Thus,
interventions targeting these viruses or the accumulated
dysfunctional memory cells specific for them [92], may be
of clinical benefit both directly against viral infection and
in terms of improving responses to vaccination. The same
principle may apply to other human populations in areas
of differing pathogen load, for example parasitic infec-
tion, rather than herpesvirus infection [150]. In addition
to pathogens, here we have argued that tumors, which are
probably very common in the elderly but not clinically
apparent in most, and which are immunogenic, are also
likely to contribute [104]. Therefore, strategies to reduce
these sources of chronic antigenic stimulation could have
a general immunorestorative role on age-associated
immune dysfunction.Immunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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The presence of cancer is commonly associated with com-
promised immune responses [95]; surgical removal of the
tumour can result in restoration of immunity [151]. By
analogy, reducing the antigenic load in the elderly, for
example, by applying antiviral agents, might be beneficial
(although some of these agents may themselves be immu-
nosuppressive [152]. Alternatively, the failure of the
immune system to entirely eliminate persistent herpesvi-
rus infection may represent a trade-off with some actual
benefits to the host; at least in mice (but only middle-aged
were tested....), infection with a virus that is similar to
human CMV seems to confer protection against infection
with certain bacteria [153]. The mechanism for this
appears to be by maintaining a higher level of pro-inflam-
matory mediators in the periphery, especially IFNγ; how-
ever, this could be part of the problem, protective in the
young, but detrimental in the elderly. So, we may again be
seeing a trade-off between pro-inflammatory status con-
ferring protection against infection in early life but anti-
inflammatory status conferring an advantage in later life
[154].
Vaccination
One of the greatest practical health-care challenges in the
elderly is to ensure that vaccinations are optimally effec-
tive. Increasing the efficacy of influenza vaccination
would have an enormous impact on health and well
being, but other vaccinations, including those currently
under development for treating cancer [155] will also
become more important in this respect. Effective vaccina-
tion may not only protect against the specific pathogen,
but also may result in enhanced activity of the NK-cell sys-
tem, which in turn may be associated with better specific
vaccine responses [119]. A combination of improved vac-
cines with better adjuvants and immunostimulatory
agents would be of further benefit, as the commonly
applied adjuvant alum is only marginally effective in the
elderly [156] and in fact mostly enhances antibody
responses, whereas resistance to viruses and cancer may
benefit more from enhanced cellular immunity [90].
There is great promise in using TLR ligands that strongly
enhance immunization efficacy and IL-2 production
[157]. The putatively dysfunctional CMV-specific
CD8+CD28- T cells that accumulate in the elderly and that
seem to be anergic and apoptosis-resistant directly ex vivo
may be restored to functional competence by culturing
them with IL-2. In this respect, they behave like anergic T
cells in many experimental systems, in which alternative
approaches including blocking inhibitory receptors, such
as PD1 mentioned above, can restore T-cell function in sit-
uations of chronic antigen exposure [158]. One option
could be therefore to treat the elderly with recombinant
IL-2; an early study reported that 39 elderly people given
well-tolerated low-dose IL-2 just before receiving influ-
enza virus vaccination produced higher antibody titres
and were better protected than controls vaccinated with-
out IL-2 pre-treatment [159]. A more recent study using a
novel IL-2-supplemented liposomal vaccine in 48 elderly
people also found better responses with IL-2 [160]. It
remains extremely important to confirm and extend these
studies.
The requirement for improved vaccination protocols
applies not only to infectious disease but possibly also to
vaccination against cancer, primarily a disease of the eld-
erly, as illustrated by differences in responses to anticancer
vaccinations in young and old mice [161]. Clearly, how-
ever, vaccination can only be effective if cells that are capa-
ble of responding are still present in the repertoire. These
may be either naïve cells to be stimulated with vaccine
containing novel antigens, or memory cells requiring
boosting by previously encountered antigen. For naïve
cells, as discussed above, the main question is whether old
individuals still have any towards the end of their lives
and if so, whether they are fully functional. In mice, naïve
T cells from old animals do seem to be impaired [162].
CD4+ T cells show decreased helper activity and IL-2 pro-
duction [163], which can nevertheless be partially
restored by exposure to a mixture of pro-inflammatory
cytokines (IL-1, IL-6 and TNF) [164]. Thus, judicious local
use of these cytokines as adjuvants might be beneficial.
However, in elderly humans, there may be vanishingly
few naïve cells remaining that could be targeted in this
way [165].
Concluding remarks
If the elderly must mostly rely on their memory T cells for
pathogen and cancer control in later life, it becomes cru-
cial to know whether these are retained and function nor-
mally [166], and if not, what can be done about it. In
mice, depletion of the dysfunctional naïve T cells can
result in their replacement by functional recent thymic
emigrants [163]. This approach, coupled with thymic
regeneration and HSC maintenance, could have a marked
clinical impact. Better understanding of immune dysfunc-
tion in human ageing will increase the probability of dis-
covering means to restore appropriate function and
alleviate the burden of infectious disease and cancer late
in life, and may possibly also benefit younger cancer
patients as well. Key questions remaining are the relative
importance of age-associated alterations in adaptive and
innate immunity, especially NK activity, to human health
and longevity; the relative roles of CMV-vs-other persist-
ent infections, such as with parasites rather than viruses,
in accelerating immunosenescence and their impact on
areas of immunity other than T cell immunity; whether
pathogen load and tumor antigen load act additively or,
worse, synergistically, in hastening immunosenescenceImmunity & Ageing 2008, 5:11 http://www.immunityageing.com/content/5/1/11
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and, obviously, how to intervene effectively to reconsti-
tute appropriate immune function throughout life.
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